GLP-1 Drug Exenatide Protects Ovaries from Chemotherapy Damage in Rat Study | Research

The takeaway

Exenatide significantly protected ovarian follicles and reduced fibrosis in rats receiving cisplatin chemotherapy, acting through anti-inflammatory NLRP3, Nrf-2, and TLR4 pathways.

Follicles preserved at all stages
Exenatide maintained primordial through tertiary follicle counts near healthy control levels in cisplatin-treated rats

What the researchers found

In rats receiving cisplatin chemotherapy for 5 weeks:

Exenatide-treated group (Group 2) vs cisplatin-only group (Group 1):

- Significantly higher numbers of primordial, primary, secondary, and tertiary follicles

- Significantly lower ovarian fibrosis percentage

- Higher plasma anti-Mullerian hormone (indicating better preserved ovarian reserve)

- Lower NLRP3 inflammasome levels (reduced inflammation)

- Lower TLR4 levels (reduced innate immune activation)

- Lower Nrf-2 levels (indicating less oxidative stress burden)

Exenatide-treated rats had ovarian parameters closer to the healthy control group (Group 0), demonstrating meaningful protection.

Why it matters

Chemotherapy-induced ovarian damage is a devastating side effect for young women with cancer, often leading to premature menopause and infertility. Currently, there are limited options to protect ovaries during chemotherapy beyond freezing eggs or embryos. If exenatide — an already-approved drug with a well-known safety profile — can protect ovarian function, it could be repurposed as a fertility-preserving treatment during cancer therapy.

How the study worked

Twenty-one female Wistar rats were divided into three groups: healthy controls (n=7), cisplatin + saline (n=7), and cisplatin + exenatide 20 μg/kg/day (n=7). Cisplatin was administered intraperitoneally twice weekly for 5 weeks to create ovarian damage. Outcomes included follicle counts at all developmental stages, ovarian fibrosis assessment, plasma anti-Mullerian hormone levels, and inflammatory pathway markers (NLRP3, Nrf-2, TLR4).

What this study cannot tell us

This is a small animal study with only 7 rats per group. The cisplatin dosing protocol may not perfectly replicate clinical chemotherapy regimens used in humans. The 5-week duration is short, and long-term ovarian function was not assessed. The study did not evaluate whether fertility was actually preserved (no mating/pregnancy outcomes). The exenatide dose used (20 μg/kg) may not directly translate to human dosing. No human studies of GLP-1 drugs for ovarian protection have been conducted.

How to read the evidence

This is a small preclinical animal study with 7 rats per group. While the results are statistically significant and biologically plausible, the small sample size and lack of functional outcomes (fertility testing) limit the strength of evidence. These findings are hypothesis-generating and require validation in larger animal studies and human trials.

When this study was published

Published in 2024, this study reflects the growing interest in repurposing GLP-1 drugs for organ protection beyond metabolic disease. The concept of using GLP-1 agonists for fertility preservation during chemotherapy is a novel and emerging research direction.

The bigger picture

GLP-1 receptor agonists continue to show protective effects in organs beyond their traditional metabolic targets. This study adds ovarian protection to the growing list that includes heart, brain, kidney, and liver benefits. The anti-inflammatory mechanism (NLRP3, TLR4 pathways) aligns with what's been seen in other organ protection studies, suggesting GLP-1 drugs have broad tissue-protective properties that extend far beyond glucose and weight control.

Questions still open

Would exenatide or other GLP-1 drugs protect ovarian function in women receiving cisplatin-based chemotherapy?
Does the ovarian protection translate to preserved fertility, and can animals still conceive after treatment?
Could GLP-1 drugs protect other reproductive organs from chemotherapy damage, such as testicular tissue in men?

Common questions

Could GLP-1 drugs protect fertility during chemotherapy?

This rat study suggests it's possible — exenatide preserved ovarian follicles and reduced damage from cisplatin chemotherapy. However, no human studies have been done yet. Current fertility preservation options during chemotherapy include egg/embryo freezing and ovarian tissue preservation. If GLP-1 drugs are confirmed to protect ovaries in humans, they could become an important additional option.

How does cisplatin damage the ovaries?

Cisplatin causes ovarian damage through three mechanisms: oxidative stress (producing harmful free radicals), inflammation (activating the NLRP3 inflammasome and TLR4 pathways), and fibrosis (scarring that replaces healthy tissue). Exenatide appeared to counteract all three mechanisms, preserving ovarian follicles at every developmental stage and maintaining anti-Mullerian hormone levels — a key marker of ovarian reserve.

Read the original research

Exenatide improves cisplatin induced ovarian damage through NLRP3, Nrf-2, and TLR4 pathways.

Cirugia y cirujanos, 93(1), 35-40

View on PubMed ↗Publisher’s paper ↗

Citation

Doğan, Gül O; Erbaş, Oytun. (2024). Exenatide improves cisplatin induced ovarian damage through NLRP3, Nrf-2, and TLR4 pathways.. Cirugia y cirujanos, 93(1), 35-40. https://doi.org/10.24875/CIRU.23000304